Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LSD1 inhibition restores MHC class I expression and augments the anti-tumor response of immune checkpoint blockade in small cell lung cancer
    Meeting Abstract

    Sen, T.; Nguyen, M. N.; Taniguchi, H.; Chow, A.; De Stanchina, E.; Rudin, C. M.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
    Meeting Abstract

    Prenen, H.; Kyi, C.; Van Lancker, G.; Patel, S. P.; Mittag, D.; Weaver, A.; Bol, K.; Stalbovskaya, V.; Pulini, J.; Zhou, G.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor
    Meeting Abstract

    Adusumilli, P. S.; Amador, A. M.; Chintala, N.; Hou, Z.; Offin, M.; Pineda, J.; Senechal, B.; Quach, H. T.; Bellis, R.; Banerjee, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Neoantigen-reactive CD8 T-cells experience broadened and activated recognition profile following PD-L1 blockade and 1000-fold neoantigen-specific expansion using ImmPACT scaffolds
    Meeting Abstract

    Sejerø Holm, J.; Funt, S. A.; Tvingsholm, S. A.; Borch, A.; Bajorin, D. F.; Reker Hadrup, S.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase I dose escalation of IMC-C103C, a CD3xMAGE-A4 T-cell receptor (TCR) bispecific protein
    Meeting Abstract

    Davar, D.; Sweis, R. F.; Blumenschein, G. Jr; Gutierrez, R.; Melero, I.; Chen, H. A.; Thistlethwaite, F.; Moore, K. N.; Segal, N. H.; Garralda, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
    Meeting Abstract

    Kris, M. G.; Grindheim, J. M.; Chaft, J. E.; Lee, J. M.; Johnson, B. E.; Rusch, V. W.; Bunn, P. A.; Pass, H.; Schum, E.; Carlisle, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Meeting Abstract

    Ramalingam, S. S.; Balli, D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Bartolucci, R.; Audigier-Valette, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Paired tumor-normal sequencing provides insights into the TP53-related cancer spectrum in patients with Li-Fraumeni syndrome
    Journal Article

    Ceyhan-Birsoy, O.; Selenica, P.; Chui, M. H.; Jayakumaran, G.; Ptashkin, R.; Misyura, M.; Aypar, U.; Jairam, S.; Yang, C.; Li, Y.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Compositional flux within the intestinal microbiota and risk for bloodstream infection with gram-negative bacteria
    Journal Article

    Stoma, I.; Littmann, E. R.; Peled, J. U.; Giralt, S.; van den Brink, M. R. M.; Pamer, E. G.; Taur, Y.
    Clinical Infectious Diseases (2021)

    Fulltext@MSK | Save
  • Predictors of enrollment of older smokers in six smoking cessation trials in the lung cancer screening setting: The Smoking Cessation at Lung Examination (SCALE) Collaboration
    Journal Article

    Eyestone, E.; Williams, R. M.; Luta, G.; Kim, E.; Toll, B. A.; Rojewski, A.; Neil, J.; Cinciripini, P. M.; Cordon, M.; Foley, K.; more...
    Nicotine & Tobacco Research (2021)

    Fulltext@MSK | Save